Serum s100β -: A noninvasive marker of blood-brain barrier function and brain lesions
Serum s100β -: A noninvasive marker of blood-brain barrier function and brain lesions
复制标题
DOI：
10.1002/cncr.11409
复制
发表时间：
2003-06-01
期刊：
影响因子：
6.2
通讯作者：
Janigro, D
中科院分区：
文献类型：
--
作者：
Kanner, AA;Marchi, N;Janigro, D
背景。单链蛋白由脑星形胶质细胞组成表达。脑外伤、蛛网膜下腔出血和脑卒中后脑脊液和血清中s100 β水平升高与脑损伤程度相关。由于血清单肽肽水平升高也显示在没有明显脑损伤的情况下血脑屏障（BBB）功能障碍，目前尚不清楚血清单肽肽水平升高是否反映血脑屏障功能障碍、实质损伤或两者兼有。作者对6例因原发性中枢神经系统淋巴瘤而接受高渗血脑屏障破坏（BBBD）伴动脉内化疗的患者进行了血清s100 β水平的前瞻性研究。此外，对51例在神经刺激时患有各种原发性或转移性脑病变的患者的53份血清s100 β样本进行了测量。s100 β与参加高渗研究的患者BBBD的临床和放射学症状的程度直接相关。在脑肿瘤患者中，钆。与非增强扫描（n = 8例患者，0.069 +/- 0.04马克杯/升）相比，磁共振图像增强与s100 β水平升高相关（n = 45例患者；0.16 +/- 0.1马克杯/升；平均+/-标准误差平均值）。原发性脑肿瘤（n = 8例，0.12 +/- 0.08）或中枢神经系统转移也出现血清s100 β水平升高（n = 27例，0.14 +/- 0.34）。只有前庭神经鞘瘤患者（n = 6例；0.13 +/- 0.10马克杯/升）的肿瘤体积与血清s100 β水平相关，而其他脑病变患者的肿瘤体积与血清s100 β水平无关。s100 β与高渗血脑屏障的范围和时间序列直接相关，进一步表明s100 β是血脑屏障功能的标志物。s100 β水平升高可能表明存在放射学可检测的血脑屏障渗漏。更大规模的前瞻性研究可能会更好地确定Sloop作为血脑屏障功能标记物的真正特异性，以及作为脑肿瘤的早期检测或随访标记物。(C) 2003年美国癌症协会。
BACKGROUND. Sloop protein is expressed constitutively by brain astrocytes. Elevated S100beta levels in cerebrospinal fluid and serum reported after head trauma, subarachnoid hemorrhage, and stroke were correlated with the extent of brain damage. Because elevated serum Sloop also was shown to indicate blood-brain barrier (BBB) dysfunction in the absence of apparent brain injury, it remains unclear whether elevation of serum levels of Sloop reflect BBB dysfunction, parenchyrnal damage, or both.METHODS. The authors conducted a prospective study of serum S100beta levels in six patients who underwent hyperosmotic BBB disruption (BBBD) with intraarterial chemotherapy for primary central nervous system lymphoma. In addition, 53 serum S100beta samples were measured in 51 patients who had a variety of primary or metastatic brain lesions at the time of neuroirnaging.RESULTS. S100beta was correlated directly with the degree of clinical and radiologic signs of BBBD in patients who were enrolled in the hyperosmotic study. In patients with neoplastic brain lesions, gadolinium. enhancement on a magnetic resonance image was correlated with elevated S100beta levels (n = 45 patients; 0.16 +/- 0.1 mug/L; mean +/- standard error of the mean) versus nonenhancing scans (n = 8 patients; 0.069 +/- 0.04 mug/L). Primary brain tumors (n = 8 patients; 0.12 +/- 0.08) or central nervous system metastases also presented with elevated serum S100beta levels (n = 27 patients; 0.14 +/- 0.34). Tumor volume was correlated with serum S100beta levels only in patients with vestibular schwannoma (n = 6 patients; 0.13 +/- 0.10 mug/L) but not in patients with other brain lesions.CONCLUSIONS. S100beta was correlated directly with the extenet and temporal sequence of hyperosmotic BBBD, further suggesting that Sloop is a marker of BBB function. Elevated S100beta levels may indicate the presence of radiologically detectable BBB leakage. Larger prospective studies may better determine the true specificity of Sloop as a marker for BBB function and as an early detection or follow-up marker of brain tumors. (C) 2003 American Cancer Society.